3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Polycythemia Vera
6
Thrombocythemia, Essential
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Myeloproliferative Disorders
2
Melanoma
2
Solid Cancers
1
Skin Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome
1
Neoplasms
1
Neoplasm of Uncertain Malignant Potential
1
Neoplasm Metastasis
1
Leukemia, Myeloid, Acute
1
Hepatitis C, Chronic
1
Glioma
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Blast Crisis
1
Interventions
fludarabine phosphate
38
Cyclophosphamide
37
Peripheral Blood Stem Cell Transplantation
32
Busulfan
28
Tacrolimus
26
Whole-Body Irradiation
20
Mycophenolic Acid
19
Methotrexate
17
Antilymphocyte Serum
17
ruxolitinib
16
fludarabine
14
Filgrastim
13
Cyclosporine
12
Melphalan
11
Radiotherapy
9
Etoposide
9
thymoglobulin
8
Psychiatric Rehabilitation
8
Prednisone
8
Methylprednisolone
8
Cytarabine
6
Cord Blood Stem Cell Transplantation
6
Thiotepa
5
Sirolimus
5
Imatinib Mesylate
5
Flow Cytometry
5
Azacitidine
5
Alemtuzumab
5
sargramostim
4
merphos
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Primary Myelofibrosis
×
peginterferon alfa-2a
×
Clear all
NCT01387763
2022-04-27
DALIAH
Odense University Hospital
Phase 3
Completed
202 enrolled